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ReviewMelarsoprol Resistance in African
TrypanosomiasisAlan H. Fairlamb1,2 and David Horn1,3,*Highlights
Arsenical monotherapies were pre-
viously very successful for treating
human African trypanosomiasis (HAT).
Melarsoprol resistance emerged as
early as the 1970s and was wide-
spread by the late 1990s.
Melarsoprol resistance represents the
only example of widespread drug
resistance in HAT patients where the
genetic mechanism has been
established.
The current goal of elimination of HAT
as a public health problem by 2020
may be undermined by the emergence
and spread of resistance to current or
new drugs.
Insights into potential resistance
mechanisms for current and new
drugs will facilitate predictions of the
likelihood of resistance and will also
facilitate rational approaches to mini-
mizing, monitoring, and tackling the
future emergence of resistance.
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d.horn@dundee.ac.uk (D. Horn).Arsenicals were introduced as monotherapies for the treatment of human
African trypanosomiasis, or sleeping sickness, over 100 years ago. Toxicity
has always been an issue but these drugs have proven to be both effective and
quite durable. Unfortunately, melarsoprol-resistant parasites emerged as early
as the 1970s and were widespread by the late 1990s. Resistance was due to
mutations affecting an aquaglyceroporin (AQP2), a parasite solute and drug
transporter. This is the only example of widespread drug resistance in trypano-
somiasis patients for which the genetic basis is known. This link between
melarsoprol and AQP2 illustrates how a drug transporter can improve drug
selectivity but, at the same time, highlights the risk of resistance when the drug
uptake mechanism is dispensable for parasite viability and virulence.
A further advantage of combined therapy is this, that under the inﬂuence of two different
medicaments the danger of rendering the parasite immune to arsenic, naturally a very great
obstacle in connexion with further treatment, is apparently minimized
Paul Ehrlich, 1913
African Trypanosomiasis Drugs and Drug Resistance
The African trypanosomes (see Glossary), Trypanosoma brucei gambiense and Trypano-
soma brucei rhodesiense, cause chronic and acute human African trypanosomiasis (HAT), or
sleeping sickness (gHAT in west Africa and rHAT in east Africa, respectively). These parasites
are transmitted to mammals by the tsetse ﬂy vector, with humans being the main reservoir for
gHAT and game animals for rHAT. In the early stages of infection with T. b. gambiense, by far
the commonest form of the disease, symptoms are less severe but the parasites eventually
cross the blood–brain barrier in most patients and, once in the central nervous system (CNS)
cause the severe neurological symptoms of the disease, which commonly culminate in coma
and death [2]. This key biphasic disease process has important implications in terms of
diagnosis and treatment. Since many drugs fail to cross the blood–brain barrier and enter
the cerebrospinal ﬂuid (CSF), and those that do often come with associated risks, diagnostics
that provide staging information are essential; this typically involves a blood test that, if positive,
progresses to a CSF test [3]. Cases are currently relatively low and the focus is on elimination as
a public health problem by 2020. However, it should be remembered that there have been
major epidemics in the past where historical periods characterised by low numbers of cases
have been followed by resurgence [4]. Chemotherapy and vector control strategies have had a
major impact on disease control but parasite reservoirs persist in animals and in trypanotolerant
individuals [5], presenting a substantial challenge in the absence of a vaccine [6].
Historically, most patients were only diagnosed once symptoms progressed to those associ-
ated with CSF involvement, meaning that CSF-penetrant drugs were particularly important. TheTrends in Parasitology, June 2018, Vol. 34, No. 6 https://doi.org/10.1016/j.pt.2018.04.002 481
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Glossary
African trypanosomes: a group of
closely related parasites typically (but
not always) restricted to Africa due to
transmission by tsetse ﬂies, with a
geographically limited range.
Trypanosoma brucei gambiense and
Trypanosoma brucei rhodesiense
infect humans and animals.
Trypanosoma brucei brucei,
Trypanosoma congolense, and
Trypanosoma vivax infect livestock
and wild animals. Trypanosoma
evansi and Trypanosoma
equiperdum infect horses, camels, or
water buffalo and cause surra and
dourine, also in Asia and Latin
America. Other related
trypanosomatids, Trypanosoma cruzi
and Leishmania spp., are transmitted
by distinct vectors displaying different
global distribution and cause distinct
diseases.
British anti-Lewisite: a heavy metal
chelator developed during World War
II as an antidote to Lewisite, an
arsenic-based chemical warfare
agent.
Flagellar pocket: a ﬂagellum-
associated invagination of the parasite
plasma membrane and the exclusive
site for endocytosis where several
receptors are concentrated [97].
Melarsoprol: a 398 Da arsenical
compound ﬁrst introduced for HAT
therapy in the 1940s. A combination
of melarsen oxide and British anti-
Lewisite.
Nagana: animal African
trypanosomiasis; a disease of cattle
and other livestock characterized by
fever and lethargy and typically
caused by T. vivax or T. congolense.
Pentamidine: a 346 Da amidine
compound ﬁrst introduced for HAT
therapy in the 1940s and used to
treat gHAT prior to CNS involvement.
Safety index: the ratio of the lowest
dose that elicits no serious toxicity
(no-observed-adverse-effect level,
NOAEL) to that which achieves
efﬁcacy to the disease. Sometimes
expressed as LD10/ED90 in animal
studies.
Therapeutic index: the ratio of the
‘lethal’ dose causing 50% death
(LD50) in animals to the ‘effective’
dose required to cure 50% (ED50).
For ethical reasons this has been
replaced by the ratio of ED50/TD50 –
the ‘toxic’ dose that causes serioustypically less toxic but poorly CSF-penetrant drugs used for the ﬁrst stage of the disease are
pentamidine for gHAT and suramin for rHAT [7]. The sufﬁciently CSF-penetrant drugs used for
the second stage of the disease are melarsoprol, the only drug available until the 1990s, and
NECT, or nifurtimox-eﬂornithine combination therapy [7,8]. Although it is often said that the
drugs mentioned above suffer from problems of drug resistance, melarsoprol resistance is
actually the only concrete example of clinically relevant drug-resistant parasites.
The Development of Arsenic-Based Therapies
Inorganic arsenical compounds have been extensively used for nearly 2500 years as both
poisons and therapeutic agents. The ﬁrst recorded use of arsenic in the treatment of trypano-
somiasis was in 1858 [9]. Although the cause of nagana, or animal trypanosomiasis, was not
known at the time, David Livingstone treated a ‘ﬂy-struck’ mare with ‘two grains of arsenic in a
little barley daily for about a week’ or Fowler’s solution (a popular tonic containing 1%
potassium arsenite; Figure 1A, Key Figure). Although the mare showed an initial improvement
in condition, it ultimately succumbed to the disease. It was not until 1902 that laboratory
conﬁrmation of the trypanocidal activity of arsenite in infected rodents was demonstrated by
Laveran and Mesnil at L’Institut Pasteur [10]. Unfortunately, all animals either died from infection
if treatment was discontinued or from arsenic toxicity if not.
In 1905, a more selective organic arsenical, optimistically named ‘Atoxyl’ (arsanilic acid;
Figure 1A), was demonstrated to show therapeutic efﬁcacy in mice by Thomas and Breinl
at Liverpool, and in 1907 Robert Koch stated that ‘no doubt can any longer exist as to the
speciﬁc action of [Atoxyl]’ [11]. This pentavalent compound had previously been dismissed by
Ehrlich and Hata in Frankfurt, however, as it lacked trypanocidal activity in vitro. It was the
pivotal discovery of Thomas and Breinl that resurrected Ehrlich and Hata’s interest in organic
arsenicals, leading to the discovery in 1910 of arsphenamine (compound ‘606’, Salvarsan) for
the treatment of syphilis. Meanwhile, the extensive use of Atoxyl for the treatment of HAT
patients had revealed serious toxicity issues, particularly blindness due to optic nerve damage.
This stimulated further research, leading to the discovery of tryparsamide (Figure 1A) by Jacobs
and Heidelberger at the Rockefeller Institute in 1919 [12].
By 1925 clinical trials in the Belgian Congo established that tryparsamide was highly effective,
especially in treating late-stage disease. However, by the late 1940s, treatment failure with
tryparsamide had become widespread (>80%) in the Belgian Congo and French Cameroun.
Meanwhile, Ernst Friedheim was developing a novel series of melaminophenyl arsenical
compounds. An entertaining autobiographical account of his observation that feeding Swiss
cheese to HAT patients ameliorated the neurotoxicity of melarsen oxide reveals how he came to
combine the heavy metal chelator British anti-Lewisite (BAL, dimercaprol) with melarsen
oxide to produce melarsoprol (MelB, Arsobal; Figure 1A) [13]. By 1950, melarsoprol was found
to be highly effective (97%) against tryparsamide treatment failures; however, by the turn of the
century, its therapeutic value against gHAT had been eroded by extensive treatment failures,
particularly in the Democratic Republic of the Congo (Figure 1B). Although NECT has largely
supplanted melarsoprol in West Africa for the treatment of gHAT, melarsoprol is still in use today
in East Africa as the only effective treatment for advanced stage rHAT. The reader is referred to
reviews for a more detailed history of arsenic in medicine [14] and in HAT [15]. Although
melarsoprol has been unfairly disparaged as ‘arsenic in antifreeze’ it has saved countless lives
since its introduction for HAT treatment in 1949. Also noteworthy, arsenic as a therapeutic has
also undergone resurgence with arsenic trioxide used for the treatment of acute promyelocytic
leukemia [16].unwanted side effects in animals.
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Treatment failure (treatment
relapse): this can be due to multiple
reasons: the drug, the patient, the
clinician, or the infecting organism.
Examples: variations in drug
metabolism and pharmacokinetic
behaviour in different patient
populations, poor quality or
substandard drugs, poor patient
compliance, clinical errors in drug
administration, different tissue
tropism of parasite strains, parasite
dormancy, reinfection, or drug
resistance.Clinical Pharmacology and Toxicology of Melarsoprol
The treatment schedule for melarsoprol in the 1950s was derived empirically. The drug is
almost insoluble in water and is administered intravenously as a 3.6% solution in propylene
glycol. This solvent is highly irritant to tissues and has to be given in glass syringes as it slowly
dissolves plastic syringes. Until recently, treatment used to start with incremental doses (to
anticipate potential drug toxicity) with ‘rest intervals’ between treatment series (presumably to
avoid cumulative drug toxicity) [7]. However, a concise 10-day treatment schedule of 2.2 mg/kg
daily has now replaced previous regimens, as it is equally efﬁcacious but considerably more
cost-effective for gHAT [17,18] and rHAT [19]. Melarsoprol is rapidly metabolised in vivo to other
trypanocidal metabolites (possibly melarsen oxide) [20,21], and melarsoprol is not detectable in
the CSF. The active metabolites in CSF achieve only about 3% of the plasma trough level [20].
Elimination is via the urine [20] and bile [22]. The safety index for melarsoprol or melarsen oxideKey Figure
Arsenicals and Melarsoprol-Resistant Trypanosomiasis
Democratic Republic of the Congo:
2001–2003: 25% failure
2005–2008: 50% failure
1940s to mid 1990s
>95% eﬀecve
The spread of 
melarsoprol resistance 
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1999: 20% failure
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1999: 30% failure
Angola:
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Figure 1. (A) Arsenical drugs and the years they were introduced for the treatment of African trypanosomiasis. (B) Melarsoprol was highly effective, but resistance was
widespread by the late 1990s and was linked to AQP2 mutation more recently. The broken line indicates the range of Trypanosoma brucei gambiense (West) and
Trypanosoma brucei rhodesiense (East).
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is 5 in mice infected with T. b. rhodesiense [23], and the therapeutic index is 50–100 for
melarsoprol in T. equiperdum infections in mice [13].
The most important serious side effect of melarsoprol treatment is post-treatment reactive
encephalopathy (PTRE) that typically occurs 1–10 days after the start of treatment. PTRE is
characterised by increased mental deterioration followed by coma and, in some cases,
convulsions and death. PTRE occurs in 5–10% of melarsoprol-treated patients, with an overall
fatality rate of about 50%. The pathogenesis of PTRE is not fully understood [24], but is
proposed to involve an immune reaction resulting from rapid lysis of trypanosomes in the CNS,
rather than drug toxicity, as survivors of PTRE are usually able to resume treatment with no
further serious adverse events [25]. However, PTRE can occur in stage I HAT patients; and
arsenical encephalopathies have been reported with melarsoprol for leukaemia [26], with a
phenylarsenoxide derivative for solid tumours [27], with arsenic trioxide for metastatic carci-
noma [28], and with various organic arsenicals in the treatment of syphilis [29]. The integrity of
the blood–brain barrier that prevents entry of most drugs into the CNS is compromised in stage
II HAT [30], and restoration of a functional blood–brain barrier following partial treatment might
also account for the lack of toxicity once melarsoprol therapy is resumed.
Treatment with prednisolone has been reported to reduce the incidence and mortality from
PTRE in gHAT [31–33], although the situation is less clear for rHAT [7,34,35]. Unfortunately, the
optimised 10-day melarsoprol therapy failed to reduce the incidence of PTRE in either gHAT
[17] or rHAT [19].
Mode of Action of Melarsoprol
The mechanism of action of arsenical drugs is not clear. Organic arsenicals can exist as either
valence +3 or +5. Pentavalent arsenicals are inactive against African trypanosomes in vitro and
have to be converted in vivo by reduction to the biologically active trivalent forms [36]. Trivalent
arsenical compounds have an afﬁnity for sulfhydryl groups, particularly vicinal (neighbouring)
thiols on proteins, but this is a rather nonspeciﬁc effect since arsenite and aminophenylarsene
oxide lack any cellular selectivity between host and parasite. Indeed, as described below,
selective toxicity is primarily conferred via selective uptake of melaminophenyl arsenicals by the
parasite-speciﬁc P2 adenosine transporter (AT1 gene) and aquaglyceroporin 2 (AQP2).
Once within the cell, the primary event appears to be reaction with the dithiol form of trypanothione
to form a 1:1 complex known as Mel T [37]. Mel T is a moderately potent competitive inhibitor of the
pivotal antioxidant enzyme, trypanothione reductase, but deﬁnitive evidence that this is the major
mechanism leading to cell death is lacking [38]. Knockdown of trypanothione synthetase and
trypanothione reductase supports the idea that MelT is toxic to the cell [39], but the precise
mechanism remains elusive. Bloodstream forms of T. brucei rapidly lose motility when exposed to
trivalent phenyl arsenoxides such as melarsen oxide, suggesting that inhibition of energy metab-
olism via glycolysis is involved in cell death. However, a careful study concluded that inhibition of
glycolysis is not the cause, but rather the consequence, of cell lysis [40]. Thus, the putative target
responsible for rapid cell lysis remains to be identiﬁed, and the possibility that arsenicals interact
with a critical membrane component has not been explored.
Studies on Laboratory-Acquired Melarsoprol Resistance
Melarsoprol Transport and Cross-Resistance with Amidines
Paul Ehrlich ‘the father of chemotherapy’ and colleagues ﬁrst described drug resistance over
100 years ago and this work was based on laboratory studies using trypanosomes [1]. Efforts to
understand arsenical resistance have since included contributions from Frank Hawking [41]484 Trends in Parasitology, June 2018, Vol. 34, No. 6
(father of the late theoretical astrophysicist Stephen Hawking), and have been linked to efforts
to understand amidine resistance, since cross-resistance between these two structurally
unrelated classes of drugs was reported in 1951 [42]. Subsequent studies have conﬁrmed
that selection for resistance to melarsoprol typically yields cross-resistance to pentamidine and
vice versa [43,44]. Resistance was found to be due to reduced drug uptake for both melarsen
oxide [45] and pentamidine [46,47]. Arsenical efﬂux is another possible mechanism of resis-
tance, and overexpression of the ABC transporter multidrug resistance protein A (MRPA) does
indeed result in melarsoprol resistance [48]. This was not the case in a mouse model, however,
and no MRPA overexpression was detected in melarsoprol-resistant isolates from HAT patients
[48].
The ﬁrst trypanosome transporter linked to arsenical and amidine cross-resistance was the P2
adenosine transporter in T. b. brucei [46,49]. Functional cloning in yeast was subsequently
used to identify the AT1 gene that encodes this transporter, which also rendered the yeast
susceptible to melarsen oxide [50]. Gene knockout was used to generate cells lacking AT1, and
these cells were approximately twofold resistant to both melarsoprol and pentamidine [51]. It
may have seemed at that time then that the genetic basis of melarsoprol–pentamidine cross-
resistance was clear. There was more to the story, however. The correlation between mutant
AT1 alleles and melarsoprol resistance remained incomplete after extensive study; see [52–54]
for example. In addition, it was possible to select cells lacking AT1 for higher levels of resistance
and this involved the loss of a ‘high-afﬁnity pentamidine transporter’ (HAPT) function in both T.
b. brucei and T. b. gambiense [44].
AQP2 Is a Melarsoprol–Pentamidine Transporter
As described above, a powerful approach for investigating mechanisms of drug resistance is to
select resistant parasites in the laboratory and then to identify the underlying changes, both
pharmacological and genetic. Indeed, it was a variation on this theme that revealed a candidate
for the gene encoding the HAPT. Genome-scale screens were used to perturb each gene
individually and to ask which genes affected melarsoprol or pentamidine resistance [39]. This
RNA interference target-sequencing (RIT-seq) approach took advantage of RNA interference to
knockdown gene expression and to ask which knockdowns rendered parasites drug resistant.
Notably, only one locus in the genome was linked to cross-resistance to both drugs and this
locus encoded two related aquaglyceroporins, AQP2 and AQP3 [39].
Aquaglyceroporins are among the major intrinsic protein family and typically facilitate the
passive transport of water and small solutes across membranes [55]; Peter Agre was awarded
a share of the 2003 Nobel Prize in Chemistry for his discovery of the related aquaporins. AQPs
had previously been considered as potential entry routes for small-molecule drugs [56], and
several such channels can transport low-molecular-mass arsenite and antimonite [57]. Indeed,
Leishmania donovani is sensitive to low-molecular-mass antimonials due to uptake via
LdAQP1, and drug resistance appears to have emerged in visceral leishmaniasis patients
in the Indian subcontinent due to loss of LdAQP1 function [58]; widespread resistance lead to
the recommended withdrawal of these drugs in this region. One hypothesis is that exposure to
arsenic in drinking water may have resulted in cross-resistance to antimonials [59]. Although
evidence supporting this hypothesis has been obtained in animal models [60], deﬁnitive clinical
epidemiological evidence is still lacking [61].
Although the ﬁndings above suggested a drug-transport mechanism, as the name suggests,
AQPs typically transport only water and small solutes, such as glycerol, not far larger com-
pounds such as melarsoprol and pentamidine. Nevertheless, a functional assessment of bothTrends in Parasitology, June 2018, Vol. 34, No. 6 485
AQPs showed that AQP2, which is restricted to the parasite ﬂagellar pocket, was speciﬁcally
responsible for drug uptake [62]. AQPs generally form tetramers and this study also suggested
that AQP2 and AQP3, although closely related, form only homotetramers that partition to
distinct membrane compartments. Importantly, cells lacking AQP2 remained susceptible to an
arsenical that diffuses across membranes, supporting a role in drug transport. AQP2 was also
shown to be dispensable with no loss of parasite ﬁtness in cell culture or in a rodent model [62].
T. brucei cells express three aquaglyceroporins (AQP1-3; Figure 2). While AQP1 and AQP3
contain the conserved dual Asn-Pro-Ala (NPA) ‘selectivity ﬁlter’ motifs and the aromatic Arg (ar-
R) motif that form prominent constrictions in the solute channel, AQP2 is unusual and has Asn-
Ser-Ala (NSA) and Asn-Pro-Ser (NPS) motifs and also lacks a conserved ar-R [63] (Figure 3),
potentially explaining the passage of larger substrates. Indeed, a single change, addition of an
ar-R within the selectivity ﬁlter, blocked drug transport by AQP2 [64]. Further genetic dissection
and ectopic expression in Leishmania mexicana cells, combined with pharmacological studies,
revealed that AQP2 does indeed encode an activity that is indistinguishable from that of the
previously described HAPT [65].
AQP2 Is Mutated in Melarsoprol-Resistant Laboratory Strains
The connection between AQP2 and drug resistance, although unexpected, prompted an
assessment of the AQP2 locus in the various strains selected for melarsoprol or pentamidine
resistance in the laboratory. The ﬁrst cross-resistant laboratory-selected strain analysed was a
T. b. brucei strain, engineered to lack AT1 and selected for increased pentamidine resistance.
This strain was found to have a chimeric AQP2/3 gene in place of the two adjacent AQPs [62]AQP2
T. b. brucei 
T. b. gambiense 
T. vivax
T. congolense  
AQP3
AQP2 AQP3
AQP3
SEC13
SEC13
SEC13 NSP
NSP
NSP
AQP3SEC13 NSP
SEC13 NSP
T. b. gambiense (40 AT) 
AQP2/3
(A) (B) TbAQP2: Tb927.10.14170 
TbAQP3: Tb927.10.14160 
TbgAQP2: KM282035
chimera 
TcAQP3: TcIL3000_10_12040 
TbAQP1: Tb927.6.1520 
TvAQP3: TvY486_1013610 
LbAQP1: LBRM2903_000007900 
LmxAQP1: LmxM.30.0020 
LmjAQP1: LmjF.31.0020 
EmAQP1:
EMOLV88_310005100
CfAQP1: CFAC1_270006300 
LsAQP1: Lsey_0007_0780 
LiAQP1:
LinJ.31.0030
LdAQP1: LdBPK_310030.1 
0.1
Figure 2. AQP2-related Genes in Trypanosomatid Genomes. (A) The African trypanosome AQP2–AQP3 locus on chromosome 10. The genomes indicated in
the smaller box are known to be (40 AT isolate) or are expected to be resistant to melarsoprol and pentamidine since they lack an intact AQP2 gene. Indeed, the 40 AT
Trypanosoma brucei gambiense isolate is melarsoprol resistant while Trypanosoma congolense and Trypanosoma vivax appear to be naturally refractory to
melarsoprol. The African trypanosome AQP1 gene is on chromosome 6 (not shown). SEC13, secretory factor; AQP, aquaglyceroporin; NSP, nuclear segregation
factor. (B) Phylogenetic tree showing the relationship between AQP2 and an AQP2/3 chimera (orange oval) and other trypanosomatid genes. The Trypanosoma brucei
(Tb), T. b. gambiense (Tbg), Trypanosoma brucei rhodesiense and Trypanosoma evansi AQP1 and AQP2 genes are almost identical (only Tb is shown for these genes).
A probable duplication event leading to AQP2 and AQP3 is indicated (blue dot). Leishmania donovani (Ld) AQP1 mutation leads to antimonial resistance, and closely
related genes are found in other Leishmania species and related species (light blue oval). The Trypanosoma cruzi genome does not encode syntenic orthologues of
these genes. Abbreviations: Tv, T. vivax; Tc, T. congolense; Ls, Leptomonas seymouri; Cf, Crithidia fasciculata; Em, Endotrypanum monterogeii; Li, Leishmania
infantum; Lmj, Leishmania major; Lmx, Leishmania mexicana; Lb, Leishmania braziliensis. Scale bar: phylogenetic distance.
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(A) (B)
(D)(C)
Figure 3. Structure Prediction of the Tetrameric AQP2 Membrane Transporter. The panels show top (A,B) and
side (C,D) views. The cut-away views (B,D) show the location of a leucine reside (red) in place of the more usual aromatic
arginine found in other AQPs. A central potential pore (visible in A,B) is not thought to be involved in drug uptake [64].
Images created using SWISS-MODELi and PyMOL.ii(see Figure 2A). These studies were extended to additional T. b. brucei, T. b. gambiense, and T.
b. rhodesiense cross-resistant laboratory-selected strains, which all revealed either chimeric
AQP2/3 genes (Figure 2A) or complete loss of AQP2 [65,66]. Notably, AT1 was also absent or
mutated in the strains above. It should be noted here that both genes may be prone to deletion/
disruption due to their positions in the genome; AT1 is located in a notoriously fragile,
subtelomeric region, and AQP2 is in tandem with AQP3. In the latter case, a DNA break
can be repaired by recombination between adjacent and shared blocks of sequence identity,
resulting in gene fusion or deletion. These studies extended the drug-resistance connection
with AQP2 and AT1 to human-infective T. b. gambiense and T. b. rhodesiense parasites, to
strains selected for either arsenical or amidine resistance [65,66], and also established that
parasites lacking both transporters were both viable in a rodent model and could be transmitted
by tsetse ﬂies [65–67].
Loss of AQP2 Function Explains Melarsoprol Resistance in Patients
Melarsoprol remained effective in patients for some time but treatment failures were wide-
spread by the late 1990s; relapse rates following treatment for gHAT were reported at 20–50%Trends in Parasitology, June 2018, Vol. 34, No. 6 487
in Angola [68], the Democratic Republic of the Congo [69], South Sudan [70], and Northern
Uganda [71], and resistant isolates from rHAT patients were also reported in Tanzania [72]
(Figure 1B). On the one hand, resistance could have emerged due to the drug pressure applied
since the 1940s, either from mass pentamidine chemoprophylaxis or as a result of widespread
melarsoprol treatment. On the other hand, treatment failure does not necessarily reﬂect the
presence of drug-resistant parasites [73,74].
The laboratory studies above showed that uptake of both melarsoprol and pentamidine by
trypanosomes is under the control of both the P2 adenosine transporter and AQP2 [65]. This
drug transport certainly improves drug efﬁcacy and potency against parasites versus host since
similar transport mechanisms are not thought to operate in mammalian host cells. However,
this comes with a risk of resistance because the transport mechanisms appear to be dispens-
able for parasite viability [51,62]. Thus, both AQP2 and AT1 emerged as candidates that may
underpin drug resistance in patients, and the more recent emergence of AQP2 as a candidate
presented an opportunity to revisit clinical isolates for further analysis.
Work with clinical isolates is generally more challenging than work on laboratory (adapted)
strains since many trypanosomes from patients fail to grow readily in standard culture medium,
some standard laboratory manipulations may be less efﬁcient, and there are additional safety
concerns; the laboratory strains that we typically work with are T. brucei brucei, which, unlike T.
b. gambiense and T. b rhodesiense, are sensitive to lytic factors in human serum [75]. Thus, an
important step in understanding clinical drug resistance is to assemble a panel of strains for
analysis in the laboratory, which was carried out for T. b. gambiense strains from patients before
treatment and after melarsoprol treatment failure [76].
The strains above were categorised as either melarsoprol-susceptible or melarsoprol-resistant,
and the AQP2 locus was then assessed, revealing speciﬁc loss of AQP2, or a novel chimeric
AQP2/3 gene (Figure 2A) in every resistant strain [77]. Notably, the AT1 gene was intact in these
isolates [77]. A subsequent study, with a larger number of clinical isolates, also linked chimeric
AQP2/3 genes, but not AT1 mutation, to melarsoprol resistance, with chimeras in isolates
dating back to 1974 [73]. Another important step was to demonstrate that reintroduction of
AQP2 into a clinical resistant T. b. gambiense isolate fully restored susceptibility to melarsoprol
(and pentamidine) while the AQP2/3 chimera failed to do so [78]. These experiments conﬁrmed
that, in patients, the AQP2 gene alone can account for drug sensitivity, and for resistance when
defective.
Studies on AQP2 illustrate the steps required to unequivocally demonstrate a clinical impact for
a genetic mutation. First, parasite samples must be isolated from patients, ideally before and
after they have relapsed after treatment. These isolates must then be propagated in the
laboratory (may require adaptation both in vivo in a rodent model and in vitro) and shown
to be resistant (compared to the initial isolate or a related susceptible isolate). A defect in the
candidate gene must then be identiﬁed (in its expression or protein-coding sequence). The
defect must then be corrected genetically and shown to restore drug sensitivity. This full set of
criteria have been satisﬁed for the AQP2 gene using a melarsoprol-relapsed patient isolate from
the Democratic Republic of the Congo (see Figure 2A, 40 AT [after treatment] isolate, [78]).
Distinct AQP2/3 chimeras found in clinical isolates suggest that resistance arose independently
on multiple occasions [73].
The situation has remained unresolved in the case of AT1. AT1 is disrupted in some resistant
strains selected in the laboratory [66] and appears to be mutated in some resistant clinical488 Trends in Parasitology, June 2018, Vol. 34, No. 6
Outstanding Questions
Can essential drug-uptake mecha-
nisms be exploited to deliver more
durable therapies?
Are all clinical cases of melarsoprol
resistance due to AQP2 defects? Does
AT1 make a contribution?
How do melarsoprol and pentamidine
interact with AQP2? Do they pass
through the channel or are they taken
up by a mechanism involving
endocytosis?
What are the resistance mechanisms
to the previous clinically used arseni-
cals such as tryparsamide?
How do trivalent aromatic arsenicals
induce rapid cell death by membrane
lysis? Could this lead to a new target
for drug discovery?
Will AQP2-defective and melarsoprol-
resistant parasites differ in their sus-
ceptibility to new antitrypanosomal
drugs?
Will rational combination therapies be
used in the future to minimize, delay, or
prevent drug resistance?isolates [54,73], but several resistant clinical isolates have wild-type copies of the AT1 gene
[53,73,77]. Thus, selection for melarsoprol or pentamidine resistance in the laboratory and
melarsoprol resistance in clinical isolates always involves loss of AQP2 function. Current
ﬁndings suggest no associated loss of virulence in patients or in transmission competence
in the tsetse ﬂy vector. Thus, AQP2 status is a valuable genetic marker for predicting the
presence of drug-resistant parasites. It may not be a reliable genetic marker for predicting
clinical outcome, however, as a number of other factors can also lead to treatment failure
[73,74].
Impact on Other Therapies
Fortunately, safer treatment options are now available for HAT, and a 2013 World Health
Organisation report stated that ‘today, there is no place for melarsoprol in the treatment of
gambiense HAT, apart from the treatment of relapses’ [79]. Results of trials of pairwise
combinations of melarsoprol, eﬂornithine, and nifurtimox in Uganda were reported in 2006
[80], and nifurtimox–eﬂornithine emerged as the favoured combination [8]. Melarsoprol-resis-
tant parasites do not display cross-resistance with eﬂornithine or nifurtimox, and the probability
of resistance emerging to this combination would appear to be low. The evidence indicates,
however, that prior drug pressure had a major impact on the prevalence of parasites that lack
AQP2 circulating in patients (Figure 1B), which may impact other therapies. For example, since
cross-resistance is typically observed in the laboratory, we might expect that AQP2-defective,
melarsoprol-resistant parasites would also be associated with pentamidine treatment failure.
This connection is not as straightforward as it might seem, however, since pentamidine failure
may be due to parasites reinvading the bloodstream from the CNS. By contrast, the gHAT cure
rate for pentamidine has remained at around 95% for decades [79]. This suggests that both
stage diagnosis is effective and also that parasites lacking AQP2 are still effectively eliminated
by pentamidine, likely because this drug is maintained at sufﬁciently high levels in serum to
remain effective. We suspect that melarsoprol also remains effective against non-CNS para-
sites lacking AQP2. Thus, a low safety index can mean that even a small shift in resistance has a
major clinical impact (such as in the case of melarsoprol against CNS-resident parasites) while a
substantial shift in resistance can be overcome if a drug has a higher safety index (such as in the
case of pentamidine against non-CNS-resident parasites).
AQP2 has an impact on another class of potential drugs, the trypanosome alternative oxidase
(TAO) inhibitors. In contrast to the situation with pentamidine, parasites lacking AQP2 are
hypersensitive to these inhibitors, due to the toxic accumulation of glycerol [81]. Indeed, the
major livestock parasites that cause nagana are susceptible to the TAO inhibitor ascofuranone
[82], and the absence of AQP2 in T. vivax and T. congolense (Figure 2) may provide an
explanation. This, combined with the absence of a functional homologue of the P2 adenosine
transporter in T. congolense [83] may also explain why this parasite is naturally refractory to
melarsoprol. Indeed, the AT1 gene is found only in the T. brucei subspecies, and the absence of
the P2 adenosine transporter in T. congolense and T. vivax likely also explains reduced
sensitivity to diminazene, a veterinary drug typically used against these parasites [84].
Concluding Remarks and Future Perspectives
Melarsoprol and melarsoprol resistance have had a huge impact on HAT control over the past
70 years. Indeed, melarsoprol resistance represents the only example of widespread drug
resistance in HAT patients, and the genetic mechanism has been established only recently.
Several questions remain regarding melarsoprol’s mode of action and potential resistance
mechanisms, however (see Outstanding Questions), and we highlight some of them below.Trends in Parasitology, June 2018, Vol. 34, No. 6 489
First, a general question that emerges from our understanding of melarsoprol resistance is
whether drugs can be designed to be more durable if they enter parasites via essential transport
processes; unfortunately, AQP2 is dispensable, as is AT1 [51] and the eﬂornithine transporter
[85]. Endocytosis is a potential delivery route and is essential for parasite survival. Indeed,
suramin is taken up by receptor-mediated endocytosis [39,86], and endocytosis can be
co-opted for the delivery of other drugs, even circumventing resistance mechanisms [87].
Second, relatively few melarsoprol-resistant clinical isolates have been examined in detail to
date and it remains unclear whether AT1, UBP1 [66], or other genes contribute to resistance.
Further functional dissection of AT1 mutations [88] and genetic screening of clinical isolates,
combined with drug-sensitivity testing, will help to provide an answer to this question. Third, the
question as to how melarsoprol and pentamidine are taken up into parasites by AQP2 persists.
These drugs may be taken into parasites by transit through the AQP2 pore or by
AQP2-mediated endocytosis. Both mechanisms have been proposed for pentamidine
[64,84]. An observation potentially consistent with uptake by receptor-mediated endocytosis
is potent inhibition of glycerol transport, involving pentamidine binding to AQP2 [64].
Unfortunately, membrane-associated proteins typically present greater challenges for structure
determination. Currently, we can model the AQP2 structure (Figure 3) but direct structural
determination, possibly with ligands bound, would help to resolve this question. Transport
assays combined with expression in heterologous systems may also be informative.
To conclude, insights into drug mode of action and resistance mechanisms facilitate drug
discovery and development and the design of optimal (combination) therapies and dosing
strategies [89]. This knowledge can also be used for surveillance and, potentially, to tackle
resistant parasites when they arise; studies on melarsoprol resistance have effectively
illustrated these principles. We should now ensure that we also develop our understanding
of the mode of action and potential resistance mechanisms for other current and new drugs
under development against HAT, such as fexinidazole [90–92] and the oxaborole, acoziborole
or SCYX-7158 [93–95], as well as for oxaboroles for the treatment of nagana [96]. We believe
that this information will help to minimize, delay, or prevent future resistance in the clinic and will
facilitate efforts to ultimately eliminate trypanosomiasis as a public health problem.
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